Award
NIH Reporter #3U01DK143379-01S1
Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report
Recipient
HealthPartners Institute
Award Amount
$1,542,828.00
Ceiling
$1,542,828.00
Awarded
September 17, 2026
Identifier
3U01DK143379-01S1
A National Institutes of Health research award supporting a trial and monitoring tools to assess ketosis risks and help prevent diabetic ketoacidosis in people with type 1 diabetes, including those with chronic kidney disease.
Description
The project will conduct an open-label trial of sotagliflozin in people with type 1 diabetes, with and without chronic kidney disease, using continuous ketone monitoring to identify ketosis risk factors and develop and refine an enhanced combined glucose and ketone report to support prevention of diabetic ketoacidosis.